Form 4: Avidity Biosciences CEO Sarah Boyce Executes Stock Options and Sells Shares

Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares of common stock in multiple transactions on March 8 and March 12, 2024.

Summary

• Sarah Boyce, CEO of Avidity Biosciences, executed stock options to acquire 84,000 shares on March 8, 2024, and 28,000 shares on March 12, 2024, at an exercise price of $1.24 per share.
• Simultaneously, she sold 84,000 shares on March 8, 2024, at a weighted-average price of $21.3894 and 28,000 shares on March 12, 2024, at a weighted-average price of $22.6315.
• Following these transactions, Boyce directly owns 112,117 shares of Avidity Biosciences common stock and 901,015 stock options.
• The stock options are fully vested and exercisable as of the date of the report, with an expiration date of December 17, 2029.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are a routine part of the stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• Shareholders may interpret the CEO's stock sales in various ways, potentially affecting investor confidence.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates